CCM
EVOK

Corsair Capital Management’s Evoke Pharma EVOK Stock Holding History

Corsair Capital Management’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,667
Closed -$55.5K – 126
2024
Q3 		$55.5K Buy
+11,667
New +$61.5K 0.01% 112

Other funds holding EVOK

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Corsair Capital Management's EVOK Position: Q4 2024 in Review

Corsair Capital Management sold out of Evoke Pharma (EVOK) in Q4 2024, closing a stake of 11,667 shares — an estimated $55.5K sold.

Corsair Capital Management first reported a position in EVOK in Q3 2024 and held it in 1 quarter. The position peaked at $55.5K in Q3 2024. 8 funds tracked by Wall St. Rank hold EVOK as of Q4 2024.

  • Corsair Capital Management reported no remaining Evoke Pharma position as of Q4 2024 after selling out during the quarter.
  • Corsair Capital Management sold 11,667 Evoke Pharma shares in Q4 2024, an estimated $55.5K.
  • Corsair Capital Management first reported a position in Evoke Pharma in Q3 2024 and held it in 1 quarter.
  • Corsair Capital Management's Evoke Pharma position peaked at $55.5K in Q3 2024.
  • 8 funds tracked by Wall St. Rank held Evoke Pharma as of Q4 2024.

Based on Corsair Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.